Bresnahan, RebeccaWilliamson, JohnMartin-McGill, Kirsty J.Michael, Benedict D.Marson, Anthony G.2019-10-312019-10-312019-10-22Bresnahan, R., Martin‐McGill, K. J., Williamson, J., Michael, B. D., & Marson, A. G. (2019). Clobazam add‐on therapy for drug‐resistant epilepsy. Cochrane Database of Systematic Reviews, (10). https://doi.org/10.1002/14651858.CD004154.pub510.1002/14651858.CD004154.pub5http://hdl.handle.net/10034/622778This article is not available on ChesterRepEpilepsy affects approximately 1% of the population, with up to 30% of patients continuing to have seizures, despite antiepileptic drug treatment. Clobazam is a 1,5‐benzodiazepine and is commonly used as an add‐on treatment for drug‐resistant epilepsy. This review is an updated version of the original Cochrane Review, first published in 2008, and examines the most current literature regarding clobazam as an add‐on for drug‐resistant epilepsy.Article2019-10-31